Cytapex Bioinformatics

Cytapex Bioinformatics Inc. eliminates barriers in high-throughput/high-dimensional cytometry data by providing expert services in data management, quality control, and data analysis, including customized gating and biomarker discovery pipelines. Their clients include basic researchers, clinicians, testing service providers, large pharmaceutical companies, and clinical trial teams. They aim to demonstrate the feasibility of automated analysis in analyzing low-quality samples and measuring ambiguously expressed checkpoint marker PD-L1 through both automated and manual methods in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and healthy donors (HD).